NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Outcomes from a Cell Viability Pre-Conference Workshop: Fit-For-Purpose Considerations for Cell Viability Measurements in Cell and Gene Therapy
Published
Author(s)
Laura Pierce, Sumona Sarkar, Leo Chan, Bo Lin, Jean Qiu
Abstract
Fit-for-purpose cell viability measurement methods are urgently needed for the characterization and testing of cell and gene therapy products and their manufacturing processes. A recent Cell Viability Workshop held at the virtual Cell Therapy Analytical Development Summit brought together stakeholders from academia, federal government institutes, instrument manufacturers, and cellular therapy product manufacturers to explore common challenges in viability measurements, as well as to address control measures and considerations for the selection of viability assays that are targeted toward the intended use of the biological sample. This report summarizes the key findings of the workshop and identifies needs and gaps for cell viability assay standards development.
Pierce, L.
, Sarkar, S.
, Chan, L.
, Lin, B.
and Qiu, J.
(2021),
Outcomes from a Cell Viability Pre-Conference Workshop: Fit-For-Purpose Considerations for Cell Viability Measurements in Cell and Gene Therapy, Cell and Gene Therapy Insights, [online], https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=932193
(Accessed October 9, 2025)